Saturday 17 October 2026 Export GERN’s income statement to Excel — free account

Geron Corporation

Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.

1.17 0.06 −4.88%

Follow GERN

Alert me

Market cap: $790.2M
P/E: 0.0×
Fwd P/E: −58.5×
Dividend yield: —
F-score: 3/9
Altman Z: −2.24
Beneish M: −1.70
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	—	—	—	—	—	—	—	—

Insider Ownership 5.58%

Capital & Financial Ratios $m

Market Cap 790.24

Revenue 204.56

Net Income (67.61)

Free Cash Flow (114.76)

Net Debt (182.61)

Current Ratio 6.92

Debt/Equity 0.55

P/E ratio 0.00

Fwd P/E (58.50)

P/S ratio 3.84

P/B ratio 3.59

Past 5Y EPS Growth —

This Y EPS Growth 67.31%

Next Y EPS Growth 274.12%

Next Y revenue growth 28.51%

Next 5Y EPS Growth 5.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.11%

10-year low 10-year high

P/B against its own 10 years 55.69%

10-year low 10-year high

EV/Sales against its own 10 years 0.85%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	335	408	360	303
Receivables	2	39	39	54
Inventory	—	39	117	124
Other	—	—	—	—
	341	491	520	486

	2023	2024	2025	Q'26
Payables	6	9	11	9
ST’ Debt	47	—	—	—
Other	—	20	17	21
	108	88	112	70

Compound Annual Growth %

	10y	5y	3y
Sales	17.59%	273.49%	575.71%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.74%	1.38%	41.34%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	52	57	—	—	—
’25	40	49	47	48	184
’24	0	1	28	48	77
’23	0	0	0	0	0
’22	0	0	0	0	1
’21	0	0	0	1	1
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(63)	(16)	—	—	—
’25	(48)	(27)	(14)	(22)	(111)
’24	(62)	(53)	(59)	(44)	(219)
’23	(46)	(30)	(51)	(41)	(168)
’22	(34)	(29)	(30)	(35)	(127)
’21	(33)	(18)	(23)	(22)	(96)
’20	(26)	(12)	(15)	(13)	(67)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(63)	(16)	—	—	—
’25	(48)	(28)	(13)	(22)	(111)
’24	(63)	(54)	(59)	(44)	(219)
’23	(47)	(30)	(51)	(41)	(169)
’22	(34)	(29)	(30)	(35)	(128)
’21	(33)	(18)	(23)	(22)	(96)
’20	(26)	(13)	(15)	(13)	(67)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.01)	(0.02)	—	—	—
’25	(0.03)	(0.02)	(0.03)	(0.05)	(0.13)
’24	(0.09)	(0.10)	(0.04)	(0.04)	(0.27)
’23	(0.07)	(0.09)	(0.08)	(0.09)	(0.32)
’22	(0.09)	(0.07)	(0.10)	(0.10)	(0.37)
’21	(0.09)	(0.09)	(0.08)	(0.10)	(0.35)
’20	(0.08)	(0.06)	(0.06)	(0.07)	(0.28)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.81	1.74	0.95	0.98	0.75	1.19	0.99	1.68	1.64	1.04	Analyst estimates 2026–2028 Powerpack
	High	4.77	3.15	6.99	2.14	2.40	2.36	3.06	3.84	5.34	3.68
People
People	Employees	18	18	18	46	55	72	107	141	229	258
	Revenue/emp, $m	0.34	0.06	0.06	0.01	0.00	0.02	0.01	0.00	0.34	0.71
Income, $m
Income, $m	Revenue	6	1	1	0	0	1	1	0	77	184
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	98.37	97.42
	EBT	(30)	(28)	(27)	(69)	(76)	(116)	(142)	(184)	(175)	(83)
	EBT margin, %	(479.34)	(2,621.22)	(2,534.43)	(14,901.74)	(29,888.14)	(8,335.39)	(23,808.89)	(77,690.72)	(226.73)	(45.41)
	Net income	(30)	(28)	(27)	(69)	(76)	(116)	(142)	(184)	(175)	(83)
	Depreciation	1	0	(1)	(1)	2	3	1	(9)	(12)	(5)
Per share, $
Per share, $	Revenue	0.04	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.12	0.28
	Earnings	(0.19)	(0.18)	(0.15)	(0.36)	(0.28)	(0.35)	(0.37)	(0.32)	(0.27)	(0.13)
	Cash flow	(0.12)	(0.13)	(0.12)	(0.23)	(0.25)	(0.29)	(0.33)	(0.29)	(0.34)	(0.17)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.12)	(0.13)	(0.12)	(0.23)	(0.25)	(0.29)	(0.34)	(0.30)	(0.34)	(0.17)
	Book value	0.77	0.65	1.01	0.71	0.78	0.39	0.21	0.43	0.43	0.34
	Shares, m	159	159	177	190	271	328	381	571	646	667
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	54.98	270.61	165.58	562.21	1,706.02	286.94	1,533.36	5,152.66	29.70	4.79
	P/B	2.77	2.78	0.99	1.91	2.05	3.16	11.42	4.93	8.16	3.90
	EV/Sales	36.30	181.45	12.15	264.30	1,027.29	191.21	1,328.74	4,085.70	26.87	3.87
	EV/FCF	(12.15)	(9.38)	(0.62)	(2.75)	(3.88)	(2.78)	(6.20)	(5.74)	(9.43)	(6.40)
Cash, $m
Cash, $m	Operating cash flow	(18)	(21)	(21)	(44)	(67)	(96)	(127)	(168)	(219)	(111)
	Capex	0	—	0	0	0	0	0	(1)	(1)	0
	Free cash flow	(18)	(21)	(21)	(44)	(67)	(96)	(128)	(169)	(219)	(111)
Balance, $m
Balance, $m	Working capital	108	89	159	113	169	142	104	233	403	409
	Total debt	—	—	—	3	25	51	51	82	118	120
	Net debt	(115)	(95)	(164)	(137)	(172)	(133)	(122)	(253)	(290)	(240)
	Shareholders’ equity	122	104	178	135	211	126	80	248	280	226
Returns, %
Returns, %	ROA	(21.17)	(23.21)	(18.28)	(39.08)	(34.67)	(46.75)	(68.12)	(62.99)	(35.34)	(14.34)
	ROIC	(263.57)	(206.77)	(137.01)	0.00	(122.54)	0.00	0.00	0.00	0.00	0.00
	ROE	(22.33)	(24.69)	(19.19)	(43.82)	(43.70)	(68.84)	(137.49)	(112.29)	(66.09)	(32.99)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
VSTM Verastem, Inc.	$835.9M	— (loss-making)	— (loss-making)	+1,775.43% (above 0%: growing)	n/m	−34.43% (below 0%: shrinking)	89.92%	(81.62%)	Compare
CRVS Corvus Pharmaceuticals, Inc.	$828.6M	— (loss-making)	—	—	n/m	−171.31% (below 0%: shrinking)	0.00%	0.00%	Compare
AVBP ArriVent BioPharma, Inc.	$827.9M	— (loss-making)	—	—	n/m	−51.51% (below 0%: shrinking)	—	0.00%	Compare
ARDX Ardelyx, Inc.	$814.9M	— (loss-making)	— (loss-making)	+23.77% (above 0%: growing)	n/m	+75.33% (above 0%: growing)	95.24%	(10.28%)	Compare
HELP Cybin Inc.	$807.3M	— (loss-making)	— (loss-making)	—	n/m	−25.60% (below 0%: shrinking)	0.00%	0.00%	Compare
DNA Ginkgo Bioworks Holdings, Inc.	$791.9M	— (loss-making)	— (loss-making)	−48.49% (below 0%: shrinking)	n/m	−16.38% (below 0%: shrinking)	91.47%	(290.47%)	Compare
GERN Geron Corporation	$790.2M	— (loss-making)	— (loss-making)	+17.22% (above 0%: growing)	n/m	+41.82% (above 0%: growing)	83.92%	(21.74%)
SANA Sana Biotechnology, Inc.	$740.9M	— (loss-making)	—	—	n/m	−5.46% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$821.4M	—	—	−6.94%	—	−20.99%	89.92%	(5.14%)

All 614 Biotechnology stocks →

Geron Corporation (GERN) key facts

Strength: Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024.
Geron Corporation (GERN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GERN traded at $1.17, a market capitalization of $790.2 million.
Return on equity was −33.0% and debt-to-equity 0.55.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −2.24 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.